RANCHO CORDOVA, Calif.,
April 17, 2019 /PRNewswire/ --
ThermoGenesis Corp., a wholly owned subsidiary of Cesca
Therapeutics (Nasdaq: KOOL), and a market leader in automated
cellular processing, today announced the release of the
enhanced X-MINI® CD3 Selection Kit for the
research market. The new X-MINI® CD3
Selection Kit provides distinct advantages, expanding on the
ability of the original X-MINI® kit to
select the CD3+ target cells from prepared mononuclear
cell samples or from a sample of whole blood.
The X-MINI® CD3 Selection Kit is the
first in a planned product line that will enable the selection of
numerous other cell types needed for a variety of groundbreaking
applications. Also included with the release of the new
kit is the X-MINI Pressor accessory, used in conjunction with the
X-MINI selection kits to eliminate the X-BACS™
reagent's buoyancy during the final processing steps.
"With the enhanced version of X-MINI, which is part of our
X-BACS product line, we have broadened the range of research
applications and potential users who would benefit from our
solutions," said Haihong Zhu,
President of ThermoGenesis. "There is an increasing need within the
cell-based therapeutics market for cutting-edge tools that improve
the manufacturing process, allowing development of the
highest-quality therapies, including CAR-T. Our X-BACS
products are designed to meet those needs. To that end, we aim to
release additional cell selection kits during 2019, as
ThermoGenesis further expands its X-BACS product line."
The X-MINI Pressor enables X-MINI kit users to simplify their
workflows by improving consistency and decreasing the number of
repetitive, manual processing steps required. The X-MINI Selection
Kits leverage the company's proprietary X-BACS™
platform to provide tangible advantages over traditional cell
selection technologies through a unique combination of attributes,
including ease of use, high cell recovery and reproducibility and
minimal cost. Both the newly enhanced X-MINI CD3 Selection
Kit and X-MINI Pressor are available for sale immediately.
About ThermoGenesis
ThermoGenesis develops,
commercializes and markets a full suite of solutions for automated
clinical biobanking, point-of-care applications, and automation for
immuno-oncology. The Company has developed an automated,
functionally closed CAR-TXpress™ Platform to
streamline the manufacturing process for the emerging CAR-T
immunotherapy market. For additional information, please visit:
www.thermogenesis.com.
About Cesca Therapeutics Inc.
Cesca Therapeutics
Inc. is a market leader in cell processing technologies and
autologous cell therapies for regenerative medicine. For more
information, visit: www.cescatherapeutics.com.
Company Contact:
Wendy
Samford
916-858-5191
ir@thermogenesis.com
Investor Contact:
Paula
Schwartz, Rx Communications
917-322-2216
pschwartz@rxir.com
View original
content:http://www.prnewswire.com/news-releases/thermogenesis-releases-its-enhanced-x-mini-cd3-selection-kit-for-the-research-market-300833464.html
SOURCE Cesca Therapeutics Inc.